Insider Selling: Kestra Medical Technologies (NASDAQ:KMTS) Insider Sells $197,795.20 in Stock

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) insider Traci Umberger sold 8,752 shares of the firm’s stock in a transaction that occurred on Friday, July 31st. The shares were sold at an average price of $22.60, for a total transaction of $197,795.20. Following the completion of the transaction, the insider directly owned 206,995 shares of the company’s stock, valued at $4,678,087. This represents a 4.06% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kestra Medical Technologies Stock Down 3.4%

Kestra Medical Technologies stock opened at $25.06 on Thursday. The firm has a market capitalization of $1.47 billion, a P/E ratio of -10.36 and a beta of 0.58. The company has a current ratio of 4.41, a quick ratio of 4.41 and a debt-to-equity ratio of 0.16. Kestra Medical Technologies, Ltd. has a twelve month low of $14.10 and a twelve month high of $30.00. The stock’s fifty day simple moving average is $22.78 and its 200-day simple moving average is $22.52.

Kestra Medical Technologies (NASDAQ:KMTS) last released its earnings results on Tuesday, July 14th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.08). Kestra Medical Technologies had a negative net margin of 138.35% and a negative return on equity of 57.38%. The company had revenue of $28.64 million during the quarter. As a group, equities analysts expect that Kestra Medical Technologies, Ltd. will post -2.29 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Kestra Medical Technologies

Institutional investors have recently added to or reduced their stakes in the business. Farther Finance Advisors LLC acquired a new position in Kestra Medical Technologies in the fourth quarter valued at approximately $31,000. Russell Investments Group Ltd. grew its position in shares of Kestra Medical Technologies by 43.5% in the 4th quarter. Russell Investments Group Ltd. now owns 1,563 shares of the company’s stock valued at $41,000 after buying an additional 474 shares during the last quarter. Daiwa Securities Group Inc. acquired a new stake in Kestra Medical Technologies during the 4th quarter worth $72,000. BNP Paribas Financial Markets lifted its position in Kestra Medical Technologies by 148.9% in the third quarter. BNP Paribas Financial Markets now owns 2,738 shares of the company’s stock valued at $65,000 after acquiring an additional 1,638 shares during the last quarter. Finally, Brown Brothers Harriman & Co. boosted its stake in Kestra Medical Technologies by 26.8% in the third quarter. Brown Brothers Harriman & Co. now owns 3,104 shares of the company’s stock valued at $74,000 after acquiring an additional 656 shares in the last quarter.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on KMTS. Wall Street Zen cut Kestra Medical Technologies from a “hold” rating to a “sell” rating in a research note on Saturday, July 18th. Weiss Ratings cut shares of Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, July 16th. Oppenheimer started coverage on shares of Kestra Medical Technologies in a report on Tuesday, July 21st. They set a “market perform” rating for the company. The Goldman Sachs Group dropped their price objective on shares of Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating on the stock in a research report on Thursday, April 9th. Finally, Wolfe Research set a $30.00 price objective on shares of Kestra Medical Technologies in a report on Wednesday, July 15th. Three research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Kestra Medical Technologies currently has a consensus rating of “Hold” and an average price target of $27.83.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.